Furrow Eva, Peralta Jade A, Moore A Russell, Minor Katie M, Guerrero Candace, Hemmila Charlotte R, DiCiccio Victoria, Cullen Jonah N, Friedenberg Steven G, Giger Urs
College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108, USA.
College of Veterinary Medicine & Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
Genes (Basel). 2024 Nov 30;15(12):1561. doi: 10.3390/genes15121561.
In heme degradation, biliverdin reductase catalyzes the conversion of biliverdin to bilirubin. Defects in the biliverdin reductase A gene () causing biliverdinuria are extraordinarily rare in humans, and this inborn error of metabolism has not been reported in other mammals. The objective of this study was to diagnose biliverdinuria and identify the causal variants in two adult mixed-breed dogs with life-long green urine. One of the dogs also had an unexplained regenerative anemia and mild hepatopathy. Clinicopathological evaluations, urinary mass spectroscopy, and molecular genetic studies were performed. Urine metabolic screening identified increased biliverdin concentrations in both cases relative to control dogs. Whole genome and Sanger sequencing revealed that each case was homozygous for large deletions in : UU_Cfam_GSD_1.0/canFam4 chr18:6,532,022-6,551,313 (19,292 bp) in Case 1 and chr18:6,543,863-6,545,908 (2046 bp) in Case 2. These variants were predicted to result in major truncations (ENSCAFT00805017018.1 p.[Lys117-Lys296del] and p.[Ala154fs], respectively) and loss of enzyme function. In a genomic variant database, 671 dogs from 63 breeds had coverage over these regions, ruling out homozygosity for the deletions. A gene defect for the regenerative anemia in Case 1 was not discovered. While expected to be rare, genotyping for the deletions can be used to identify other affected and carrier dogs. This study illustrates the use of targeted metabolic and genomic screening as key diagnostic tools to diagnose a rare metabolic disorder. These are the first confirmed cases of biliverdinuria caused by defects in non-human mammals.
在血红素降解过程中,胆绿素还原酶催化胆绿素转化为胆红素。导致胆绿素尿症的胆绿素还原酶A基因()缺陷在人类中极为罕见,其他哺乳动物尚未报道过这种先天性代谢缺陷。本研究的目的是诊断胆绿素尿症,并确定两只成年混种犬终生尿液呈绿色的致病变异。其中一只犬还患有原因不明的再生性贫血和轻度肝病。进行了临床病理评估、尿液质谱分析和分子遗传学研究。尿液代谢筛查发现,与对照犬相比,两只病犬的胆绿素浓度均升高。全基因组和桑格测序显示,每只病犬均为UU_Cfam_GSD_1.0/canFam4 chr18:6,532,022 - 6,551,313(19,292 bp)大缺失的纯合子,病例1为该缺失,病例2为chr18:6,543,863 - 6,545,908(2046 bp)的缺失。这些变异预计会导致主要截短(分别为ENSCAFT00805017018.1 p.[Lys117 - Lys296del]和p.[Ala154fs])并丧失酶功能。在一个基因组变异数据库中,来自63个品种的671只犬覆盖了这些区域,排除了缺失的纯合性。未发现病例1中再生性贫血的基因缺陷。虽然预计这种情况罕见,但对缺失进行基因分型可用于识别其他患病和携带变异的犬。本研究说明了使用靶向代谢和基因组筛查作为诊断罕见代谢紊乱的关键诊断工具。这些是首例在非人类哺乳动物中由缺陷导致的胆绿素尿症确诊病例。